WeSearch

Aclaris Therapeutics, Inc. (ACRS) Discusses Clinical Program Update and Progress of Lead Bispecific Antibody Candidates Transcript

SA Transcripts· ·2 min read · 0 reactions · 0 comments · 21 views
#aclaris#therapeutics#acrs#discusses#clinical
Aclaris Therapeutics, Inc. (ACRS) Discusses Clinical Program Update and Progress of Lead Bispecific Antibody Candidates Transcript
TL;DR · WeSearch summary

We bridge the gap between financial information and actionable insight by providing unrivaled coverage on all asset classes and access to best-in-class tools. Davis - President, COO & DirectorJesse Hall - Chief Medical OfficerRoland Kolbeck - Chief Scientific Officer Conference Call Participants Nathanael Charoensook - Leerink Partners LLC, Research DivisionBiren Amin - Piper Sandler & Co., Research DivisionJeffrey Jones - Oppenheimer & Co. Inc., Research DivisionNabeel Nissar - Jefferies LLC, Research DivisionAdam Vogel - Craig-Hallum Capital Group LLC, Research DivisionJillian WeissSeamus Fernandez - Guggenheim Securities, LLC, Research DivisionYu Fan - Wedbush Securities Inc., Research DivisionRaghuram Selvaraju - H.C.

Key facts
Original article
Seeking Alpha · SA Transcripts
Read full at Seeking Alpha →
Opening excerpt (first ~120 words) tap to expand

{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4895275-aclaris-therapeutics-inc-acrs-discusses-clinical-program-update-and-progress-of-lead"},"author":{"@type":"Person","name":"SA Transcripts","url":"https://seekingalpha.com/author/sa-transcripts"},"publisher":{"@context":"https://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New York","addressRegion":"NY","postalCode":"10001","addressCountry":"US"},"alternateName":["SeekingAlpha","SA"],"brand":[{"@type":"Brand","name":"Seeking Alpha Premium","url":"https://seekingalpha.com/subscriptions/premium"},{"@type":"Brand","name":"Seeking Alpha…

Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.

Anonymous · no account needed
Share 𝕏 Facebook Reddit LinkedIn Threads WhatsApp Bluesky Mastodon Email

Discussion

0 comments

More from Seeking Alpha